{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:48:53Z","timestamp":1792633733054,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["BSC0201"],"award-info":[{"award-number":["BSC0201"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bcp.2016.04.010","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T18:19:16Z","timestamp":1461953956000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy"],"prefix":"10.1016","volume":"117","author":[{"given":"Kakoli","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-0246","authenticated-orcid":false,"given":"Naibedya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.04.010_b0005","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2016.04.010_b0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jbmr.1885","article-title":"Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts","volume":"28","author":"Boyce","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2016.04.010_b0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.bcp.2016.04.010_b0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","article-title":"Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis","volume":"7","author":"Costa","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2016.04.010_b0030","first-page":"569","article-title":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7\u201329, 2000: highlights of the conference","volume":"94","year":"2001","journal-title":"South. Med. J."},{"key":"10.1016\/j.bcp.2016.04.010_b0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2016.04.010_b0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0045","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2016.04.010_b0055","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/hmg\/ddl474","article-title":"Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence","volume":"16","author":"Chen","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2016.04.010_b0070","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.04.010_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bonekey.2012.67","article-title":"Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation","volume":"1","author":"Duong","year":"2012","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.bcp.2016.04.010_b0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bone.2005.10.017","article-title":"Human osteoblasts produce cathepsin K","volume":"38","author":"Mandelin","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jbmr.2719","article-title":"Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the investigational drug with PTH, estrogen, and alendronate","volume":"31","author":"Khan","year":"2016","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0090","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":"Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization","volume":"14","author":"Gowen","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0095","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","article-title":"Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K","volume":"16","author":"Kiviranta","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/14728222.12.3.291","article-title":"Cysteine cathepsin S as an immunomodulatory target: present and future trends","volume":"12","author":"Gupta","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2016.04.010_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: a novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.04.010_b0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.addr.2004.12.013","article-title":"The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics","volume":"57","author":"Yasuda","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2016.04.010_b0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.04.010_b0120","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1359\/jbmr.080231","article-title":"Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis","volume":"23","author":"Chavassieux","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0125","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.bmcl.2005.05.062","article-title":"P2\u2013P3 conformationally constrained ketoamide-based inhibitors of cathepsin K","volume":"15","author":"Barrett","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2016.04.010_b0130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2006.07.015","article-title":"A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys","volume":"40","author":"Kumar","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0135","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.108.172320","article-title":"Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice","volume":"28","author":"Yang","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcp.2016.04.010_b0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fendo.2015.00041","article-title":"Coupling signals between the osteoclast and osteoblast: how are messages transmitted between these temporary visitors to the bone surface?","volume":"6","author":"Sims","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2016.04.010_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.beem.2014.08.002","article-title":"Future directions for new medical entities in osteoporosis","volume":"28","author":"Ferrari","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0155","first-page":"666","article-title":"Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation","volume":"123","author":"Lotinun","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2016.04.010_b0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/bj1920365","article-title":"Inhibition of bone resorption in culture by inhibitors of thiol proteinases","volume":"192","author":"Delaisse","year":"1980","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2016.04.010_b0165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/8756-3282(87)90007-X","article-title":"The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts","volume":"8","author":"Delaisse","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0006-291X(84)90560-6","article-title":"In vivo and in vitro evidence for the involvement of cysteine proteinases in bone resorption","volume":"125","author":"Delaisse","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2016.04.010_b0175","first-page":"523","article-title":"Isolation and characterization of E-64, a new thiol protease inhibitor","volume":"42","author":"Hanada","year":"1978","journal-title":"Agric. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.04.010_b0180","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0021-9258(19)69895-9","article-title":"Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases","volume":"256","author":"Green","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.04.010_b0185","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/13543776.2011.616283","article-title":"Inhibitors of cathepsin K: a patent review (2004\u20132010)","volume":"21","author":"Wijkmans","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2016.04.010_b0190","first-page":"59","article-title":"Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis","volume":"24","author":"Watanabe","year":"2014","journal-title":"Clin. Calcium"},{"key":"10.1016\/j.bcp.2016.04.010_b0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/13543780902832661","article-title":"Cathepsin K inhibitors for osteoporosis and potential off-target effects","volume":"18","author":"Bromme","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2016.04.010_b0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2202-12-74","article-title":"Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits","volume":"12","author":"Dauth","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.bcp.2016.04.010_b0205","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0002-9440(10)63777-7","article-title":"Pivotal role of cathepsin K in lung fibrosis","volume":"164","author":"Buhling","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2016.04.010_b0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1465-9921-12-72","article-title":"The effect of cathepsin K deficiency on airway development and TGF-beta1 degradation","volume":"12","author":"Zhang","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1042\/BJ20140809","article-title":"Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor","volume":"465","author":"Sharma","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2016.04.010_b0220","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bph.13383","article-title":"A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K","volume":"173","author":"Panwar","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2016.04.010_b0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00223-015-0051-0","article-title":"Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis","volume":"98","author":"Duong","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0230","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","article-title":"Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity","volume":"48","author":"Falgueyret","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2016.04.010_b0235","first-page":"S59","article-title":"Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation","volume":"21","author":"Papanastasiou","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0240","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":"Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.04.010_b0245","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2016.04.010_b0250","article-title":"Orally active CatK inhibitor, ONO-5334, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys","volume":"24","author":"Yamada","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0255","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","article-title":"Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0260","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bone.2011.09.041","article-title":"Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism","volume":"49","author":"Ochi","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","article-title":"Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts","volume":"42","author":"Fuller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0270","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1016\/j.bmc.2004.07.054","article-title":"Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: synthesis and cysteinyl proteinase inhibition","volume":"12","author":"Quibell","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2016.04.010_b0275","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00223-009-9279-x","article-title":"Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys","volume":"85","author":"Stroup","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0280","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-011-1593-2","article-title":"Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys","volume":"23","author":"Jerome","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0285","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jemt.20813","article-title":"The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients","volume":"73","author":"Chappard","year":"2010","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.bcp.2016.04.010_b0290","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","article-title":"Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib","volume":"66","author":"Runger","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bcp.2016.04.010_b0295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2008.03.009","article-title":"Drug-induced morphea: report of a case induced by balicatib and review of the literature","volume":"59","author":"Peroni","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bcp.2016.04.010_b0300","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00774-013-0542-x","article-title":"ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats","volume":"32","author":"Ochi","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.04.023","article-title":"Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys","volume":"65","author":"Ochi","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2016.04.010_b0310","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","article-title":"Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study","volume":"29","author":"Eastell","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0315","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jbmr.2080","article-title":"The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study","volume":"29","author":"Engelke","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0320","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/dmd.110.037184","article-title":"Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway","volume":"39","author":"Kassahun","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.04.010_b0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00223-013-9800-0","article-title":"The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits","volume":"94","author":"Jensen","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0330","first-page":"953","article-title":"Bone lining cells: structure and function","volume":"3","author":"Miller","year":"1989","journal-title":"Scanning Microsc."},{"key":"10.1016\/j.bcp.2016.04.010_b0335","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/jbmr.2752","article-title":"Effects of long-term odanacatib treatment on bone gene expression in ovariectomized adult rhesus monkeys \u2013 differentiation from alendronate","volume":"31","author":"Muise","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0340","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2125.2012.04471.x","article-title":"Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics\u2013results from single oral dose studies in healthy volunteers","volume":"75","author":"Stoch","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2016.04.010_b0345","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2013-1688","article-title":"Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women","volume":"99","author":"Anderson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0350","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial","volume":"26","author":"Bone","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2016.04.010_b0355","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0360","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","article-title":"Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey","volume":"27","author":"Cusick","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0365","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jbmr.2194","article-title":"Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength","volume":"29","author":"Cheung","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0370","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2016.04.010_b0375","first-page":"119","article-title":"The role of biochemical markers of bone turnover in osteoporosis management in clinical practice","volume":"27","author":"Vasikaran","year":"2006","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.bcp.2016.04.010_b0380","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study","volume":"27","author":"Langdahl","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0385","series-title":"ASBMR 2014 Annual Meeting Abstract 1147","article-title":"Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)","author":"Mcclung","year":"2014"},{"key":"10.1016\/j.bcp.2016.04.010_b0390","series-title":"ISBMR 2014 Annual Meeting Abstract","article-title":"Identification and profiling of novel series with superior profile over odanacatib","author":"Mukherjee","year":"2014"},{"key":"10.1016\/j.bcp.2016.04.010_b0395","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11832-013-0526-3","article-title":"Metachondromatosis: more than just multiple osteochondromas","volume":"7","author":"Fisher","year":"2013","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bcp.2016.04.010_b0400","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature12396","article-title":"Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling","volume":"499","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2016.04.010_b0405","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.chembiol.2012.05.013","article-title":"Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening","volume":"19","author":"Bannwarth","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2016.04.010_b0410","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.sbi.2013.08.001","article-title":"Allosteric inhibition of BACE1 by an exosite-binding antibody","volume":"23","author":"Wang","year":"2013","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bcp.2016.04.010_b0415","first-page":"678","article-title":"Tanshinone prevents cancellous bone loss induced by ovariectomy in rats","volume":"25","author":"Cui","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2016.04.010_b0420","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.bcp.2003.12.031","article-title":"Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge","volume":"67","author":"Kim","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2016.04.010_b0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/08923970801949133","article-title":"The correlation of Salvia miltiorrhiza extract-induced regulation of osteoclastogenesis with the amount of components tanshinone I, tanshinone IIA, cryptotanshinone, and dihydrotanshinone","volume":"30","author":"Kim","year":"2008","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.bcp.2016.04.010_b0430","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.abb.2011.08.006","article-title":"Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet","volume":"515","author":"Xu","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2016.04.010_b0435","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2015.08.010","article-title":"Complexity of cancer protease biology: cathepsin K expression and function in cancer progression","volume":"35","author":"Verbovsek","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2016.04.010_b0440","first-page":"619","article-title":"Recent developments in cathepsin K inhibitor design","volume":"8","author":"Grabowskal","year":"2005","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.bcp.2016.04.010_b0445","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1535-7163.MCT-14-0253","article-title":"Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis","volume":"13","author":"Duong","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2016.04.010_b0450","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1021\/jm058198r","article-title":"Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K","volume":"48","author":"Palmer","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2016.04.010_b0455","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.04.010_b0460","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/SPC.0b013e32830baea9","article-title":"Cathepsin K inhibitors as treatment of bone metastasis","volume":"2","author":"Le Gall","year":"2008","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.bcp.2016.04.010_b0465","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bcp.2016.04.010_b0470","series-title":"Odanacatib","year":"2015"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216300491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216300491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T03:26:57Z","timestamp":1718508417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216300491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":94,"alternative-id":["S0006295216300491"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.04.010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}